×

Charting

New Growth Horizons

ANNUAL REPORT | 2023-24

About Alkem Laboratories

With a presence spanning over five decades, we have enriched the industry through pioneering work aimed at making a significant impact on people’s lives.

Performance Highlights FY 2023-24

126,676 Mn

Revenue from operations

9.2%

y-o-y

22,455 Mn

Earnings before interest, tax, depreciation and amortization (EBITDA)

39.5%

y-o-y

17,958 Mn

Profit after tax (PAT)

82.5%

y-o-y

35.5 Bn

Net cash

Letter from the Executive Chairman

Dear Shareholders,

At Alkem, our credo, “Inspiring Healthier Lives” is at the core of our research-driven innovation culture, enabling us to impact millions of lives worldwide positively. Reflecting on FY 2023-24, we made considerable progress in strengthening our operations, expanding our portfolio and pipeline, integrating new capabilities, and fostering the development of our people while attracting fresh talent across the organization.

B. N. Singh Executive Chairman

Managing Director’s Communique

Dear Shareholders,

Throughout our five-decade-long journey, Alkem has consistently evolved, expanding into new categories, businesses, and markets worldwide. This transformation has created significant opportunities, enabling us to scale growth and become a leading player in the Indian pharmaceutical industry.

Sandeep Singh Managing Director

CEO’s Message

Dear Shareholders,

In my first letter to you as the Chief Executive Officer, I take great pride in reporting on the progress Alkem has made during FY 2023-24. Alongside delivering strong financial results, we achieved several operational milestones, including successful new product launches, market expansion, advancements in research and development, and improved manufacturing efficiencies, all of which have contributed to our overall growth trajectory.

Dr. Vikas Gupta Chief Executive Officer

Our Financial Prudence